vs
AVISTA CORP（AVA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是AVISTA CORP的1.4倍（$772.1M vs $533.0M），AVISTA CORP净利率更高（13.3% vs 12.7%，领先0.6%），Revvity同比增速更快（5.9% vs 0.0%），Revvity自由现金流更多（$161.8M vs $-116.0M），过去两年Revvity的营收复合增速更高（9.0% vs -6.5%）
Avista Corporation是美国能源企业，业务涵盖发电、输电及天然气配送，服务覆盖住宅、商业与工业客户。公司拥有约1550名员工，为美国西部三个州的35.9万电力用户和32万天然气用户提供能源相关服务，业务区域覆盖华盛顿州东部、爱达荷州北部、俄勒冈州南部及东部部分区域，总面积达7.8万平方公里。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AVA vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.4倍
$533.0M
营收增速更快
RVTY
高出5.8%
0.0%
净利率更高
AVA
高出0.6%
12.7%
自由现金流更多
RVTY
多$277.8M
$-116.0M
两年增速更快
RVTY
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $533.0M | $772.1M |
| 净利润 | $71.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 21.0% | 14.5% |
| 净利率 | 13.3% | 12.7% |
| 营收同比 | 0.0% | 5.9% |
| 净利润同比 | 5.7% | 3.9% |
| 每股收益（稀释后） | $0.87 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVARVTY
| Q4 25 | $533.0M | $772.1M | ||
| Q3 25 | $403.0M | $698.9M | ||
| Q2 25 | $411.0M | $720.3M | ||
| Q1 25 | $617.0M | $664.8M | ||
| Q4 24 | $532.8M | $729.4M | ||
| Q3 24 | $393.7M | $684.0M | ||
| Q2 24 | $402.1M | $691.7M | ||
| Q1 24 | $609.4M | $649.9M |
净利润AVARVTY
| Q4 25 | $71.0M | $98.4M | ||
| Q3 25 | $29.0M | $46.7M | ||
| Q2 25 | $14.0M | $53.9M | ||
| Q1 25 | $79.0M | $42.2M | ||
| Q4 24 | $67.2M | $94.6M | ||
| Q3 24 | $18.5M | $94.4M | ||
| Q2 24 | $22.9M | $55.4M | ||
| Q1 24 | $71.5M | $26.0M |
毛利率AVARVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率AVARVTY
| Q4 25 | 21.0% | 14.5% | ||
| Q3 25 | 14.9% | 11.7% | ||
| Q2 25 | 13.9% | 12.6% | ||
| Q1 25 | 20.3% | 10.9% | ||
| Q4 24 | 19.1% | 16.3% | ||
| Q3 24 | 12.4% | 14.3% | ||
| Q2 24 | 13.5% | 12.4% | ||
| Q1 24 | 16.6% | 6.8% |
净利率AVARVTY
| Q4 25 | 13.3% | 12.7% | ||
| Q3 25 | 7.2% | 6.7% | ||
| Q2 25 | 3.4% | 7.5% | ||
| Q1 25 | 12.8% | 6.4% | ||
| Q4 24 | 12.6% | 13.0% | ||
| Q3 24 | 4.7% | 13.8% | ||
| Q2 24 | 5.7% | 8.0% | ||
| Q1 24 | 11.7% | 4.0% |
每股收益（稀释后）AVARVTY
| Q4 25 | $0.87 | $0.86 | ||
| Q3 25 | $0.36 | $0.40 | ||
| Q2 25 | $0.17 | $0.46 | ||
| Q1 25 | $0.98 | $0.35 | ||
| Q4 24 | $0.86 | $0.77 | ||
| Q3 24 | $0.23 | $0.77 | ||
| Q2 24 | $0.29 | $0.45 | ||
| Q1 24 | $0.91 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.7B | $7.3B |
| 总资产 | $8.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AVARVTY
| Q4 25 | $19.0M | $919.9M | ||
| Q3 25 | $44.0M | $931.4M | ||
| Q2 25 | $9.0M | $991.8M | ||
| Q1 25 | $17.0M | $1.1B | ||
| Q4 24 | $30.0M | $1.2B | ||
| Q3 24 | $9.1M | $1.2B | ||
| Q2 24 | $14.6M | $2.0B | ||
| Q1 24 | $12.3M | $1.7B |
股东权益AVARVTY
| Q4 25 | $2.7B | $7.3B | ||
| Q3 25 | $2.6B | $7.4B | ||
| Q2 25 | $2.6B | $7.6B | ||
| Q1 25 | $2.6B | $7.6B | ||
| Q4 24 | $2.6B | $7.7B | ||
| Q3 24 | $2.5B | $7.9B | ||
| Q2 24 | $2.5B | $7.9B | ||
| Q1 24 | $2.5B | $7.8B |
总资产AVARVTY
| Q4 25 | $8.4B | $12.2B | ||
| Q3 25 | $8.2B | $12.1B | ||
| Q2 25 | $8.1B | $12.4B | ||
| Q1 25 | $8.0B | $12.4B | ||
| Q4 24 | $7.9B | $12.4B | ||
| Q3 24 | $7.8B | $12.8B | ||
| Q2 24 | $7.7B | $13.4B | ||
| Q1 24 | $7.6B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-116.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -21.8% | 21.0% |
| 资本支出强度资本支出/营收 | 35.8% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.06× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-101.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AVARVTY
| Q4 25 | $75.0M | $182.0M | ||
| Q3 25 | $170.0M | $138.5M | ||
| Q2 25 | $40.0M | $134.3M | ||
| Q1 25 | $184.0M | $128.2M | ||
| Q4 24 | $89.8M | $174.2M | ||
| Q3 24 | $127.2M | $147.9M | ||
| Q2 24 | $126.8M | $158.6M | ||
| Q1 24 | $190.1M | $147.6M |
自由现金流AVARVTY
| Q4 25 | $-116.0M | $161.8M | ||
| Q3 25 | $37.0M | $120.0M | ||
| Q2 25 | $-103.0M | $115.5M | ||
| Q1 25 | $81.0M | $112.2M | ||
| Q4 24 | $-37.8M | $149.8M | ||
| Q3 24 | $-27.0M | $125.6M | ||
| Q2 24 | $-5.7M | $136.6M | ||
| Q1 24 | $71.4M | $129.7M |
自由现金流率AVARVTY
| Q4 25 | -21.8% | 21.0% | ||
| Q3 25 | 9.2% | 17.2% | ||
| Q2 25 | -25.1% | 16.0% | ||
| Q1 25 | 13.1% | 16.9% | ||
| Q4 24 | -7.1% | 20.5% | ||
| Q3 24 | -6.9% | 18.4% | ||
| Q2 24 | -1.4% | 19.7% | ||
| Q1 24 | 11.7% | 20.0% |
资本支出强度AVARVTY
| Q4 25 | 35.8% | 2.6% | ||
| Q3 25 | 33.0% | 2.6% | ||
| Q2 25 | 34.8% | 2.6% | ||
| Q1 25 | 16.7% | 2.4% | ||
| Q4 24 | 23.9% | 3.4% | ||
| Q3 24 | 39.2% | 3.3% | ||
| Q2 24 | 33.0% | 3.2% | ||
| Q1 24 | 19.5% | 2.7% |
现金转化率AVARVTY
| Q4 25 | 1.06× | 1.85× | ||
| Q3 25 | 5.86× | 2.97× | ||
| Q2 25 | 2.86× | 2.49× | ||
| Q1 25 | 2.33× | 3.03× | ||
| Q4 24 | 1.34× | 1.84× | ||
| Q3 24 | 6.88× | 1.57× | ||
| Q2 24 | 5.55× | 2.87× | ||
| Q1 24 | 2.66× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVA
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
